Antigen recognition by the B cell receptor (BCR) is a physiological trigger for reactivation of Epstein-Barr virus 7
Introduction 29
Epstein-Barr virus (EBV) infects nearly 95% of adults worldwide. The virus primarily causes infectious 30 mononucleosis (IM) in adolescents, is closely associated with lymphoproliferative disease in 31
immunocompromised individuals, and is linked to cancers including Burkitt lymphomas (BL), diffuse large B 32 cell lymphomas (DLBCL), and nasopharyngeal carcinoma (1, 2) . BL is a common childhood cancer in Africa, 33
and >80% of cases are EBV positive (3). As a germinal-center (GC) derived cancer, BL cells exhibit a 34 centroblast-like phenotype (2, 4) , maintained in part from activated c-myc oncogene expression (5), and have a 35 molecular profile akin to GC dark zone proliferative B cells (6) . 36 EBV has both a latent and a lytic replication phase, and periodically, latent EBV reactivates to produce 37 infectious virions. The EBV lytic stage is essentially required for horizontal transmission and lifelong 38
persistence, and has a poorly understood role in the development of viral malignancies (7) . In addition to 39 epithelial cells in the oropharynx (8), resting peripheral blood and tonsil memory B cells are thought to serve as 40 reservoirs for latent EBV (2, 9) , while mature B cell trafficking through the GC and terminal differentiation into 41 CD38+ plasma cells can trigger EBV reactivation (10). In vitro, cross-linking of surface immunoglobulins (Ig) 42
on freshly isolated EBV-positive B cells (11) or latently infected BL cells (12) functionally mimics antigen 43 interactions and stimulates virus reactivation. The complex signaling events initiated through cross-linking of 44 the B cell receptor (BCR) activate EBV immediate early (IE) genes BZLF1 and BRLF1, encoding viral 45
transactivators Zta and Rta respectively, and induce the lytic cascade (7) . 46
Exact molecular mechanisms, including underlying post-transcriptional processes, controlling EBV latency and 47 the switch to lytic replication remain to be fully elucidated (7, 13) . Master transcriptional regulators of plasma 48
cell differentiation, such as Blimp-1/PRDM1, can activate the EBV Zta (Zp) and Rta (Rp) promoters (13, 14) . 49
Transcription factors such as ATF, Sp1/3, MEF2D, XBPs, CREB family members, AP1 heterodimers (i.e. c-50
Jun), and HIF1a interact with Zp in response to antigen stimulation or oxidative stress; Zp further contains cis-51 regulatory elements which confer auto-regulation (7, 13, (15) (16) (17) (18) . Repressors of Zp include the zinc finger E-52
box-binding proteins encoded by ZEB1 and ZEB2 and the polycomb protein Yin Yang 1 (YY1) (7, 13, (19) (20) (21) . 53
Notably, microRNAs (miRNAs) from the miR-200 family (miR-200b and miR-429 expressed in epithelial cells) 54 post-transcriptionally silence ZEB1/2 expression, thereby modifying Zp activity (22, 23) . 55 miRNAs are ~22 nucleotide (nt) non-coding RNAs that post-transcriptionally control gene expression and 56 regulate multiple biological processes, including B cell development, GC reactions, and the progression of 57 immune responses (24, 25) . Deregulated miRNA activity is implicated in B cell lymphomagenesis, and normal 58 B cell subtypes, as well as B cell cancers, can be distinguished by miRNA signatures (24, 26) . EBV encodes 59 >44 viral miRNAs, the majority of which are expressed from the BART locus, and exhibit expression kinetics 60 similar to the BART transcripts (27) . BART miRNAs are detectable throughout phases of EBV infection, 61
including latency I (28), suggesting these molecules actively facilitate maintenance of the latent state (29, 30) . 62
However, viral miRNA expression is rapidly induced upon entry into the lytic cycle (27, 28) , indicating a 63 possible role in EBV reactivation. Recently, we identified several EBV miRNAs that attenuate BCR signal 64 transduction and consequently, dampen BCR-induced EBV reactivation, demonstrating that a subset of the 65 viral miRNAs actively suppress lytic replication (31) . 66
The functions for most host miRNAs in EBV reactivation are not known. Subversion of apoptosis and evasion 67 of anti-viral responses are key parts of viral reactivation, and several groups have previously demonstrated 68 roles for miRNAs in these processes (30, 32) . Additionally, studies in which Dicer was inhibited reported 69 reduced levels of IE gene expression during EBV reactivation, providing evidence that components of the 70 miRNA biogenesis machinery are necessary for aspects of lytic replication (33, 34) . We previously reported 71 that disruption of cellular miR-17 in EBV-positive BL cells augments IE gene expression (31), and other groups 72 have shown that miR-200 family members expressed in epithelial cells have essential roles in the EBV latent to 73 lytic switch (22, 23) . In this study, we investigated how EBV exploits BCR-responsive cellular miRNAs to 74 navigate entry into the lytic phase. Specifically, we aimed (i) to define the miRNAs that are altered by BCR-75 mediated lytic reactivation, (ii) to elucidate targets of those miRNAs, and (iii) to determine whether BCR-76 responsive miRNAs and/or their targets play a role lytic reactivation. 77
Results

78
BCR-mediated EBV reactivation induces changes in cellular miRNA levels 79
To investigate the role of host miRNAs in EBV reactivation, we treated EBV-positive MutuI cells with antibodies 80
to surface Ig (aIgM) for 22 hrs and profiled the small RNAs by deep sequencing (<200 nt). Over one million 81 sequences were obtained per sample, and following alignment to the human and EBV genomes, 1,015 distinct 82 miRNAs (read count >1 in at least one library) were identified. Of these, 392 mature miRNAs, were considered 83 expressed (read counts >=10) and used to determine differential expression (DE) in mock versus anti-IgM 84 treated cells ( Fig. 1A ). Consistent with prior reports (27, 28) , nearly all EBV miRNAs were upregulated 85
following anti-IgM treatment ( Fig. 1A) . EBV miRNAs not shown (i.e. miR-BHRF1-2-5p) were still detected, but 86
at levels below our cut-offs. In addition to viral miRNAs, we observed significant changes in host miRNAs. miR-87 141-3p, miR-146a-5p, miR-342-3p, miR-3609, miR-21-3p, and miR-21-5p increased upon BCR stimulation 88 while 11 miRNAs, including miR-148a-5p, miR-27b-5p and miR-139-3p, significantly decreased. 89 BCR-mediated induction of miR-141-3p and miR-146a-5p were independently verified by qRT-PCR ( Fig. 1B) .
90
We measured levels of other miRNAs which have been linked to BCR stimulation and/or EBV reactivation (i.e. 91
miR-17/92, miR-181, miR-190) (37, 38), but did not detect robust changes in their expression ( Fig. 1B) .
92
Enhanced miR-146a levels have been linked to LMP1 expression (39) while miR-21 is upregulated following 93 EBNA2 expression (40) and de novo EBV infection (41). miR-342-3p is BCR-responsive in murine WEHI-231 94 cells (42). We therefore selected miR-141-3p for further analysis. While miR-141 has been studied extensively 95 in epithelial cells, less is known about this miRNA in B cells. Similar to viral BART miRNAs, miR-141-3p 96 accumulated during EBV reactivation (Fig. 1C) . 97
miR-141/200c are responsive to BCR cross-linking irrespective of EBV infection status 98
To investigate whether miR-141 induction is linked to any EBV factors, we tested additional BL cells. Surface 99
Ig cross-linking increased miR-141-3p in both EBV-negative and EBV-positive cells ( Fig. 1D ), suggesting that 100 miR-141 induction is not dependent upon EBV, but instead a cellular response to BCR signals. To definitively 101 rule out EBV as a contributor, we tested miR-141-3p levels in EBV+ BL cells expressing a doxycycline 102
inducible Zta (Akata-tet-Z) (43). In these cells, EBV reactivation can be initiated through the BCR or 103 alternatively, through direct chemical induction of Zta. Treatment of Akata-tet-Z cells with anti-IgG led to 104 increased miR-141-3p similar to what was observed for other BL cells; however, when EBV lytic replication 105 was activated independent of the BCR, miR-141-3p levels were unaffected ( Fig. 1E and F). We therefore 106
conclude that miR-141-3p induction is linked to the normal cell signaling response initiated through BCR 107 engagement and not mediated through any viral gene products. 108 miR-141 is part of the miR-200 family, consisting of five members that are processed from polycistronic 109 primary miRNA transcripts ( Fig. 2A ) (44) . While levels of other miR-200 family members were below our 110 stringent cut-offs for miRNA profiling, we observed modest increases in miR-200c in response to anti-IgM (not 111 shown), suggesting that the miR-141/200c pri-miRNA is transcribed. To explore this further, miR-200c, miR-112 429, and miR-200b levels were monitored in BL cells. Both miR-141-3p and miR-200c temporally accumulated 113 with similar kinetics ( Fig. 2B and C), consistent with activation of the pri-miRNA. In contrast, miR-429 and miR-114
200b were induced only in MutuI cells, indicating alternate modes of regulation ( Fig. 2D and E). 115
The miR-141/200c promoter contains response elements for EGR1 (45), a rapid response nuclear zinc finger 116 transcription factor that is upregulated upon BCR engagement (46). To explore EGR1 as a possible 117 mechanism for how miR-141 and miR-200c are induced, we inhibited EGR1 with short hairpin RNAs (shRNAs) 118
( Fig. 2F ). Knockdown of EGR1 attenuated but did not fully abrogate miR-141 and miR-200c induction upon 119 BCR cross-linking ( Fig. 2G and 2H ), pointing to a partial role for EGR1 in miR-141/200c transcription. 120
miR-141 contributes to EBV reactivation 121
Prior studies in epithelial cells demonstrated positive correlations between EBV lytic gene expression and miR-122
200 family members (22, 23) . To determine whether miR-141 plays a role in EBV reactivation in B cells, we 123
utilized CRISPR-Cas9 to genetically inactivate miR-141 in MutuI cells expressing a tet-inducible Cas9 (iCas9).
124
Following doxycycline treatment to activate Cas9, miRNA levels were measured by qRT-PCR, confirming 125 specific disruption of miR-141 but not miR-200c ( Fig. 3A and B ). We subsequently examined EBV reactivation. 126
Compared to control cells, disruption of miR-141 resulted in significantly reduced levels of the early EBV 127 BMRF1 protein following surface Ig cross-linking ( Fig. 3C and D). Consistent with attenuated lytic antigen 128 expression, miR-141 inhibition also yielded decreases in viral loads and IE transcripts ( Fig. 3E-G) . Thus, miR-129 141 induction conferred through BCR signaling is necessary for efficient EBV reactivation. 130 miR-141-3p and miR-BART9-3p function through common 5' seed sequences 131
Intriguingly, EBV encodes a viral miRNA, miR-BART9-3p, which exhibits seed sequence homology to miR-132 141-3p ( Fig. 4A ), leading to the hypothesis that the viral and cellular miRNAs have common targets and 133 common activities mediated through interactions with cognate seed match sites. To formally test this idea, 134
miR-141 and miR-BART9 expression vectors were co-transfected with reporters harboring perfect binding sites 135 in the luciferase 3'UTR for either miR-BART9-3p or miR-141-3p ( Fig. 4B ). As expected, both the viral and 136 cellular miRNA potently downregulated their own reporters. Notably, we observed ~40% knockdown of 137 luciferase activity when miR-141 was tested against the BART9 reporter and ~60% knockdown when miR-138
BART9 was tested against the miR-141 reporter ( Fig. 4B ). As the only stretch of sequence homology between 139 these two miRNAs is the 5' seed (nt 1-7), these results demonstrate that miR-141-3p and miR-BART9-3p are 140 capable of functionally interacting with target RNAs through common 5' sequences. 141
Cellular targets are commonly regulated by miR-141 and miR-BART9 142
To investigate biological targets of miR-141-3p and miR-BART9-3p, we assembled a list of native 3'UTR 143
interactions extracted from previously published studies (47-51). Target interactions were assigned based 144 upon canonical miRNA seed pairing (i.e. nt 2-7). Additional candidates predicted by TargetScan (52) were 145
included for a comprehensive list ( Fig. 5A ). We identified 1,880 unique 3'UTR targets harboring canonical 5' 146 seed matches to miR-141-3p, miR-200a, and/or miR-BART9-3p, of which 321 targets overlapped with one or 147 more study. Comparison of the 187 3'UTRs captured in PAR-CLIP studies revealed that 41% of interaction 148 sites could be assigned to both miR-BART9-3p and miR-141-3p based upon the presence of seed-match sites 149
(inset, Fig. 5A ). 150 miRNA interaction sites in CLIP and RNAseq studies are assigned computationally; thus, to experimentally 151 confirm targets, luciferase reporters were constructed for 14 3'UTRs. We specifically selected 3'UTRs of 152
interest to either B cell or EBV biology. These included (i) FOXO3, encoding Forkhead box O3a, a member of 153 the conserved forkhead box transcription factors (53), (ii) RANBP9, encoding an adaptor protein that interacts 154
with Zta to augment reactivation (54), (iii) YY1, necessary for GC reactions (55) and binds multiple sites within 155
Zp to repress Zta expression (21), (iv) ZCCHC3, encoding a co-sensor for cGAS (56), and (v) ZEB2, a 156 transcriptional repressor of Zp (13, 22) . Binding sites in these 3'UTRs represented a range of 6mer (nt 2-7) to 157 8mer (nt 2-9) seed matches for miR-141-3p and/or miR-BART9-3p ( Fig. 5B and C) . 158
Reporters were tested in HEK293T cells co-transfected with miRNA expression vectors. For seven 3'UTRs, we 159 observed significant inhibition of luciferase activity in the presence of either miRNA, supporting the idea that 160 miR-BART9-3p functional mimics miR-141-3p ( Fig. 5B and C). Mutagenesis of seed match sites in the 161 ZCCHC3 and ZEB2 3'UTRs was sufficient to restore luciferase activity in the presence of EBV miR-BART9-3p 162
and partially restored activity with miR-141 ( Fig. 5C ). Interestingly, luciferase assays further revealed distinct 163
targeting of CCDC6 and YY1 3'UTRs by miR-141 but not miR-BART9 ( Fig. 5B ). Presumably, these targeting 164 differences are due to 3' compensatory binding. 165
We assessed the impact of miR-141 and miR-BART9 on endogenous Foxo3a, RanBP9, and Zeb2 protein 166 levels in HEK293T cells. Foxo3a and RanBP9 were significantly reduced in response to both miRNAs ( Fig. 5D  167 and E). Surprisingly, despite the ZEB2 3'UTR responding to both miRNAs ( Fig. 4D ), we detected decreases in 168
Zeb2 only in the presence of miR-141 ( Fig. 5F ), indicating that ZEB2 is not targeted by miR-BART9. Taken 169 together, these experiments formally demonstrate that miR-BART9-3p acts as a partial mimic of miR-141-3p. 170
miR-141 regulates Foxo3a levels in BL cells 171
Having demonstrated that Foxo3a levels are responsive to ectopic miR-141, we sought to determine whether 172
FOXO3 was directly targeted by endogenous miR-141. EBV-negative Ramos-iCas9 and EBV-positive Akata-173
iCas9 cells were transduced with gRNAs to disrupt miR-141 ( Fig 6B and E) . Cells were treated with anti-Ig for 174 48 hrs and protein subsequently analyzed by immunoblotting. Compared to control cells, basal levels of 175
Foxo3a increased by two to three fold in miR-141 mutant cells ( Fig. 6A and D). miR-141 mutant cells were still 176 responsive to BCR engagement; however, Foxo3a levels were consistently higher in these cells following anti-177
Ig treatment. We further tested viral copies in Akata-iCas9 cells by qPCR. Similar to observations in Fig. 3E , 178
miR-141 disruption negatively impacted viral loads ( Fig. 6G ). Thus, perturbation of miR-141 in EBV-infected 179 cells yields higher Foxo3a expression and is detrimental to lytic reactivation. 180
miR-BART9 enhances FOXO3 repression 181
To further understand the dynamics of Foxo3a repression during EBV reactivation, we monitored protein levels 182
at multiple times post BCR stimulation ( Fig. 7A and B ). Foxo3a remained stable up until 24 hrs; by 48 hrs, 183 however, total protein levels decreased three to five fold. Notably, this coincides with maximum miRNA 184
induction (see Fig. 1 ). Similar to observations in Fig. 6 , Foxo3a levels were lower in EBV-positive cells 185 compared to EBV-negative cells, which is presumably due to miR-BART9 ( Fig. 7C ). Bypassing BCR signaling, 186
Zta-mediated reactivation had little impact on Foxo3a, suggesting that viral gene products alone are not 187 sufficient to measurably impact Foxo3a (Fig. 7C) . Given that miR-141 is consistently induced in response to 188 BCR engagement irrespective of infection status, we wondered whether miR-BART9 might exert an additive 189 effect during infection. We therefore introduced miR-BART9 into EBV-negative cells (Fig. 7D ). Ectopic miR-190 BART9 did not impact basal Foxo3a; however, upon BCR stimulation, miR-BART9 significantly enhanced 191
Foxo3a reduction (Fig. 7E ). These results indicate that the cellular environment conferred through BCR 192 signaling, combined with the presence of miR-BART9, plays a key part in Foxo3a regulation during EBV 193 reactivation. 194
FOXO3 inhibition promotes EBV reactivation 195
Foxo3a levels inversely correlated with viral loads during reactivation ( Fig. 6G ), suggesting that Foxo3a might 196 be restrictive for the lytic cycle. To test this hypothesis, we implemented shRNAs to post-transcriptionally block 197
FOXO3 in EBV-positive cells ( Fig. 8A and B ). RNAi-mediated knockdown of FOXO3 sensitized cells to 198 reactivation stimuli, and lead to significant increases in viral loads (Fig. 8A ). We carried out similar experiments 199
in EBV-positive Akata cells in which the lytic replication cycle can be activated directly through Zta. While miR-200
BART9 is expressed in these cells and accumulates in the presence of Zta, miR-141 is not induced in the 201 absence of BCR stimulation, thereby allowing us to uncouple miR-141 and BCR signaling effects from EBV 202 reactivation ( Fig. 1 and 2 ). Compared to cells transduced with control vector, we observed significant increases 203 in lytic antigen expression in shFOXO3 cells upon Zta expression ( Fig. 8C and D explain the different levels of miR-141 and miR-200c detected in these prior studies (Fig. 2) . 232
Accumulating evidence indicates that miR-141 and other miR-200 family members play crucial roles in the 233 replication of both DNA and RNA viruses. Picornaviruses, such as enterovirus 71, induce miR-141 and miR-234
200c through EGR1; miR-141-3p subsequently targets eIF4E to aid in host shut-off, thereby positively 235
impacting productive virus replication (45). Through the use of shRNAs, we show here that EGR1 is also 236 partially responsible for miR-141 induction in BL cells (Fig. 2) indirectly enhancing lytic gene expression (22, 23) . We found that miR-141 could target the ZEB2 3'UTR and 245
reduce Zeb2 levels in HEK293T cells (Fig. 5 ). However, consistent with several studies examining Zeb 246 expression in lymphocytes and other immune cell populations (63), we were unable to confirm Zeb2 247 expression in BL cells, thus prompting us to explore roles for other miR-141 targets in EBV reactivation. 248
Target identification for miR-141 in EBV-infected cells is complicated by the fact that EBV encodes a viral 249 miRNA (miR-BART9-3p) with seed sequence homology to miR-141-3p ( Fig. 4) . While it has long been 250
hypothesized that this viral miRNA might act as a functional mimic of miR-141 and/or other miR-200 family 251
members, we formally demonstrate in this study that this is indeed the case. Using luciferase reporter assays, 252
we show that multiple cellular 3'UTRs can be commonly targeted by both miR-141 and miR-BART9 (Fig. 5 ).
253
Additionally, RanBP9 and Foxo3a protein levels were suppressed in the presence of either miRNA. 254
Intriguingly, we identified two 3'UTRs (YY1 and CCDC6) that responded only to miR-141, despite strong seed 255 matches to miR-BART9-3p. Furthermore, Zeb2 levels were inhibited by miR-141 but not miR-BART9, despite 256 the 3'UTR reporter responding to both miRNAs (Fig. 5 ). While it remains to be specifically tested, these data 257 strongly suggest that base-pairing outside of the seed region dictates the exact repertoire of targets for each 258 miRNA and also contributes to the overall level of translational repression for each of their targets. 259
Given the potent inhibition of Foxo3a levels upon miR-141 or miR-BART9 expression, we selected this target 260 as a potential candidate for involvement in the EBV latent-to-lytic switch. Foxo transcription factors have a wide 261 range of functions and participate in a multitude of cellular processes including cell cycle, apoptosis, stress 262 response, and cell differentiation. Notably, chemical inhibition of one member of the Foxo family, Foxo1, 263
induces reactivation of the related human g-herpesvirus, KSHV, in adherent iSLK cells (64) for degradation by the ubiquitylation-mediated proteasome degradation pathway while interactions between 274
Foxo3a and 14-3-3 proteins result in nuclear shuttling (68). In the context of EBV infection, LMP1 can induce 275
Akt activation and phosphorylation of Foxo3a, resulting in Foxo3a translocation out of the nucleus (69). Here, 276
we demonstrate that the overall levels of Foxo3a are additionally controlled through both viral and host miRNA-277 mediated post-transcriptional regulation of FOXO3 transcripts. Through loss-of-function experiments, we 278 further establish that FOXO3 inhibition positively impacts EBV reactivation (Fig. 8 In summary, these data enhance our current understanding of how host and viral miRNAs contribute to EBV 292 reactivation. To date, the majority of studies have pointed to roles for miRNAs in supporting latent infection for 293
herpesviruses (72-74). Against convention, we demonstrate that specific miRNAs can also act to promote lytic 294 reactivation, lending support to the idea that these molecules actively orchestrate aspects of latency and 295 reactivation to cooperatively facilitate viral persistence within a host. Future work is needed to understand the 296 specific relationships between miR-141 and miR-BART9 co-regulated factors which can reveal novel 297 therapeutic targets for EBV-associated lymphomas. 298
Methods 299
Cell culture. BL cell lines were maintained at 37°C in a 5% CO2-humidified atmosphere in RPMI-1640 300
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin, streptomycin, and L-glutamine (P/S/G).
301
MutuI cells originated from the laboratory of Dr. Erik Flemington. EBV negative Akata cells were provided by 302
Dr. Renfeng Li. Akata-tetZ cells were maintained in tetracycline-free media and provided by Dr. JJ Miranda 303
with permission from Dr. Alison Sinclair. HEK293T cells were maintained in high glucose DMEM supplemented 304 with 10% FBS and 1% P/S/G. For preparation of lentiviruses, HEK293T cells were plated in 15-cm plates in 305 complete media and transfected using Polyethylenimine (PEI) with 15 ug lentivector, 9 ug pDeltaR8.75 and 6 306 ug pMD2G. Media was changed to complete RPMI-1640 between 8 hrs and 16 hrs post-transfection. 307
Lentiviral particles were harvested by sterile filtration of the supernatant using a 0.45 micron filter at 48 and 96 308 hrs post-transfection and used to transduce ~1 to 5 x 10^6 cells. For BCR cross-linking, BL cells were spun 309 down and plated at 0.5 x 10^6 cells in fresh media containing soluble anti-IgM or anti-IgG (Sigma) at 310 concentrations and times indicated in figure legends (2.5-5 ug/mL for 22-48 hrs). 311
Plasmids. pLCE-based miRNA expression vectors contain ~200 nt of the pre-miRNA as previously described 312
(47). Functional miRNA expression was confirmed by indicator assays as previously described (47) and YY1 were provided by Dr. Jay Nelson's laboratory at VGTI. Additional 3'UTR reporters are cloned into 318 pLSG as previously described (31, 47) . Oligonucleotide sequences used for cloning are available upon 319 request. Mutant 3'UTR reporters, containing nucleotide changes in miRNA seed match sites as identified by 320 PAR-CLIP, were generated by Phusion Taq site-directed mutagenesis as previously described (76). 321 CRISPR editing. Inducible Cas9 (iCas9) BL cells were established by transducing cells with pCW-Cas9-Blast-322
based lentiviruses (Addgene #83481) and selecting with Blasticidin. iCas9 cells were subsequently transduced 323
with LentiGuide-puro lentiviral vector (Addgene #52963) bearing either empty guide RNA (gRNA) as control or 324
gRNA against miR-141 and then selected with puromycin. Stable cell lines were treated with doxycycline for 7 325 days prior to analysis. Cells were treated with anti-IgM for 48 hours and lysates harvested for immunoblot 326 analysis. 327
Quantitative RT-PCR (reverse transcription-polymerase chain reaction) and PCR analysis. For gene 328 expression analysis, total RNA was extracted using TRIzol (Thermofisher), DNAse-treated, and reversed 329 transcribed using MultiScribe (Thermofisher) with random hexamers. Cellular and viral genes were detected 330
using PowerUp SYBR Green qPCR (Thermofisher). Oligonucleotides sequences are available upon request. 331
For viral loads, genomic DNA was isolated using DNAzol (Thermofisher). 100 ng of DNA were analyzed using 332
primers to the LMP1 region and normalized to GAPDH levels as previously described (31) Bowtie (v1.0.1 http://bowtie-bio.sourceforge.net/index.shtml) (-v 2 -m 10) (77)). miRNAs were annotated and 356 quantified by miRDeep (78). EdgeR (79) was used to define the significant, differentially expressed miRNAs in 357 control versus anti-IgM treated cells (p<0.05, FDR<0.05, read counts >20). Heatmaps were generated in R. 358
Raw miR-Seq data files can be accessed through NCBI short read archive (SRA) (SUB6521585, submission in 359 progress). 360
Statistical analyses. Luciferase and PCR data are reported as mean of at least three independent experiments 361 (unless otherwise stated) with standard deviations (S.D.). Statistical significance was determined by paired 362
Student's t test, performed using Microsoft Excel 2010, and values p < 0.05 were considered significant. 363
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